$VKTX | 2030 Valuation Scenarios π
Assuming successful commercialization of VK2735 (injectable + oral) in ALL three scenarios:
π» **BEAR CASE**
$1.5B revenue Γ 4x sales
β $6.5B market cap
β $42/share
π― **BASE CASE**
$3.5B revenue Γ 7x sales
β $25B market cap
β $156/share
π **BULL CASE**
$7B revenue Γ 9x sales
β $64B market cap
β $376/share
Current price: $29.22.
The thesis: A meaningful share of the obesity market through injectable, oral and potentially less-frequent maintenance treatments.
Key catalysts: Phase 3 results, regulatory approval and commercial execution.
Risks: Lilly/Novo competition, pricing pressure, dilution and margins.
5
329
I believe the long-term weight-management market could become significantly larger than it is today.
$HIMS has an interesting position through its direct-to-consumer healthcare platform and customer relationships.
The opportunity is not simply selling one treatment. It's building a broader healthcare distribution platform.
Regulation and sustainable unit economics remain key risks.
1
578
$ASTS | 2030 Valuation Scenarios π
Three possible outcomes for AST SpaceMobile:
π» **BEAR CASE**
$3β5B revenue Γ 4x sales
β $12β20B market cap
β $27β44/share
π― **BASE CASE**
$5B revenue Γ 7x sales
β $35B market cap
β $76/share
π **BULL CASE**
$10B revenue Γ 9x sales
β $90B market cap
β $188/share
Assumptions: 450Mβ480M diluted shares, depending on scenario, and net debt of $1B in the bear case and approximately zero in base/bull.
The thesis: 60+ MNO partners, 3B+ subscribers represented, and a potential global satellite cellular network.
The opportunity is enormous. Execution, capex, competition and dilution will determine the outcome.
A large backlog is encouraging, but it doesn't automatically mean value creation.
For $NBIS, I want to see contracted demand convert into operational capacity and revenue.
The most important questions are how much capital expansion requires, how it is financed and whether returns justify the investment.
Growth matters. Returns on capital matter more.
68
$ASTS is building the next layer of global telecom infrastructure.
60+ MNO partners representing 3B+ subscribers.
Commercial agreements with AT&T, Verizon, Vodafone. Rakuten JV, backed by up to $1B in Japanese government funding.
Current EV: $14B (80x 2026 sales).
The pathway:
β’ Scale BlueBird production & launches.
β’ Activate commercial coverage.
β’ Monetize existing telecom partnerships.
β’ Expand globally and drive network utilization.
2030 illustrative bull case:
$5B revenue Γ 8x EV/Sales = $40B EV (3x today's EV).
The opportunity: become a global infrastructure layer for mobile connectivity.
1
207
My investment in $BMNR is fundamentally a long-term bet on Ethereum.
I believe ETH has value beyond being a digital asset: it's also the foundation of a programmable blockchain ecosystem.
Staking adds another dimension by allowing holders to earn ETH-denominated rewards.
My horizon is 2030, not the next market cycle.
Crypto has been stuck in a range since 2021 , i believe in the next decade we will go through the range and set a new higher base.
1
1
164
rr00 retweeted
WE ARE IN A "SAFE-HAVEN" STOCK BUBBLE.
$COST β ~49Γ (Historically extreme valuation)
$WMT β ~43Γ (Near 30-year highs)
$AAPL β ~38Γ (Near 20-year highs)
$MNST β ~37Γ (Near all-time highs)
$RSG β ~33Γ (Near all-time highs)
$KO β ~29Γ (Near 25-year highs)
$JNJ β ~26Γ (Near 25-year highs)
$BRK.B β ~26Γ (Near 25-year highs)
$MCK β ~23Γ (Near 25-year highs)
$ABBV β ~19Γ (Near 10-year highs)
*Approximate forward P/E ratios.
Here's the interesting part:
These 10 companies are projected to grow EPS by just ~10% on average next fiscal year.
Investors are paying historically extreme valuation premiums for the perception of safety.
Meanwhile, the Nasdaq-100, packed with high-growth tech companies, is nearing COVID-era forward P/E lows...
While high-growth tech stocks trade at unjustifiably low multi-year valuations, Wall Street props up the indexes with historically expensive defensive stocks.
Why is nobody talking about this???
Why I own $TRET
Most of my portfolio is exposed to growth.
$TRET gives me something different: global real estate exposure.
My thesis is that interest rates have likely reached or are close to the peak of this cycle.
If rates normalize from here, real estate can benefit from:
lower financing costs β better property valuations β improved cash flows β stronger sentiment
After years of pressure from high rates, I think the risk/reward in real estate is becoming more interesting.
Iβm not expecting $TRET to grow like $PLTR or $NBIS.
It has a different role in my portfolio:
diversification + income + potential upside from a change in the rate environment.
In a portfolio full of growth, I like having one position that benefits from a completely different macro setup.
$TRET = my real estate/rates bet.
1
53
$SOFI is one of my higher-conviction positions.
At these levels, Iβm buying ,
While the stock is down , the business keeps compounding:
β’ Revenue +43% YoY
β’ Members +35%
β’ Products +42%
β’ Record loan originations
β’ 2026 revenue guidance raised
Short-term volatility doesnβt change my long-term thesis.
Iβm accumulating. $SOFI π
68
The important lesson in markets isnβt to fear every correction.
Itβs to understand the asymmetry:
π Markets can spend a long time climbing.
π They can fall very quickly.
Thatβs why risk management matters most when everything feels easy.
Even tho I feel like the last couple of years the movement has been with the elevator towards both directions π€£
$SPY $QQQ
1
29
We live in times where good data is bad for markets
Yields moving again
π΄ β οΈ BREAKING: UNIVERSITY MICHIGAN SENTIMENT FINAL ACTUAL 48.1 (FORECAST 47.5, PREVIOUS 47.8) $MACRO
26





